BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 17116665)

  • 1. Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro.
    Perkhofer S; Lugger H; Dierich MP; Lass-Flörl C
    Antimicrob Agents Chemother; 2007 Feb; 51(2):791-3. PubMed ID: 17116665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus.
    Arikan S; Sancak B; Alp S; Hascelik G; McNicholas P
    Med Mycol; 2008 Sep; 46(6):567-73. PubMed ID: 19180726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
    Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species.
    O'Shaughnessy EM; Meletiadis J; Stergiopoulou T; Demchok JP; Walsh TJ
    J Antimicrob Chemother; 2006 Dec; 58(6):1168-76. PubMed ID: 17071635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
    Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
    Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).
    Manavathu EK; Cutright JL; Loebenberg D; Chandrasekar PH
    J Antimicrob Chemother; 2000 Aug; 46(2):229-34. PubMed ID: 10933645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activities of amphotericin B and voriconazole against aleurioconidia from Aspergillus terreus.
    Lass-Flörl C; Rief A; Leitner S; Speth C; Würzner R; Dierich MP
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2539-40. PubMed ID: 15917567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
    Kaya AD; Kiraz N
    Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Short communication: In vitro activity of amphotericin B with fluconazole or voriconazole combinations against Candida albicans isolates].
    Oz Y; Akşit F; Kiraz N; Kiremitçi A
    Mikrobiyol Bul; 2008 Jan; 42(1):149-55. PubMed ID: 18444574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions.
    Perkhofer S; Jost D; Dierich MP; Lass-Flörl C
    Antimicrob Agents Chemother; 2008 May; 52(5):1873-5. PubMed ID: 18347112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model.
    Meletiadis J; Stergiopoulou T; O'Shaughnessy EM; Peter J; Walsh TJ
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2053-64. PubMed ID: 17387150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of amphotericin B and micafungin combination against clinical isolates of Aspergillus species.
    Nishi I; Sunada A; Toyokawa M; Asari S; Iwatani Y
    J Chemother; 2011 Apr; 23(2):102-6. PubMed ID: 21571627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B.
    Abraham OC; Manavathu EK; Cutright JL; Chandrasekar PH
    Diagn Microbiol Infect Dis; 1999 Jan; 33(1):7-11. PubMed ID: 9990469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B.
    Oakley KL; Moore CB; Denning DW
    J Antimicrob Chemother; 1998 Jul; 42(1):91-4. PubMed ID: 9700534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli.
    Lionakis MS; Lewis RE; Torres HA; Albert ND; Raad II; Kontoyiannis DP
    Diagn Microbiol Infect Dis; 2005 May; 52(1):15-20. PubMed ID: 15878437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species.
    Ryder NS; Leitner I
    Med Mycol; 2001 Feb; 39(1):91-5. PubMed ID: 11270414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study of fungicidal activities of voriconazole and amphotericin B against hyphae of Aspergillus fumigatus.
    Krishnan S; Manavathu EK; Chandrasekar PH
    J Antimicrob Chemother; 2005 Jun; 55(6):914-20. PubMed ID: 15824093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp.
    Philip A; Odabasi Z; Rodriguez J; Paetznick VL; Chen E; Rex JH; Ostrosky-Zeichner L
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3572-4. PubMed ID: 16048988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole.
    Sutton DA; Sanche SE; Revankar SG; Fothergill AW; Rinaldi MG
    J Clin Microbiol; 1999 Jul; 37(7):2343-5. PubMed ID: 10364610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp.
    Lewis RE; Wiederhold NP; Klepser ME
    Antimicrob Agents Chemother; 2005 Mar; 49(3):945-51. PubMed ID: 15728887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.